References
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders4th. American Psychiatric Association, Washington, DC 2000; 66–71
- Bailey A, Le Couteur A, Gottesman I, Bolton P, Simonoff E, Yuzda E, Rutter M. Autism as a strongly genetic disorder: Evidence from a British Twin Study. Psychol Med 1995; 25(1)63–77
- Cook EH. Genetics of autism. Child Adolesc Psychiatr Clin N Am. 2001; 10: 333–50
- http://www.autismwebsite.com/ari/dan/mercurymetaldetox.htm, Autism Research Institute. Treatment options for mercury/metal toxicity in autism and related developmental disabilities: consensus position paper. February 2005
- 5. MICROMEDEX(R) Healthcare Series Vol. 127, expires 3/2006.
- Chemet, Ovulation Pharmaceuticals, Inc. Thomson PDR. Physicians' Desk Reference59th. Chemet, Ovulation Pharmaceuticals, Inc., Montvale, New Jersey 2005; 2566–2568
- Sue YJ. Mercury. Goldfrank's Toxicologic Emergencies. Appleton and Lange, Stamford, CT 1998; 1328
- Byers RK, Maloof CC. Edathamil calcium-disodium (Versenate) in treatment of lead poisoning in children. Am J Dis Child 1954; 87: 559
- Bentur Y, Brook JG, Behar R, Taitelman V. Meso-2,3-dimercaptosuccinic acid in the diagnosis and treatment of lead poisoning. J Toxicol Clin Toxicol 1987; 25: 39–51
- Frumkin H, Manning CC, Williams PL, Sanders A, Taylor BB, Pierce M, Elon L, Hertzberg VS. Diagnostic chelation challenge with DMSA: A biomarker of long-term mercury exposure?. Environ Health Perspect 2001; 109: 167–71
- Lee BK, Schwartz BS, Stewart W, Ahn KD. Provocative chelation challenge with DMSA and EDTA: evidence for differential access to lead storage sites. Occup Environ Med 1995; 52: 13–19
- Roels HA, Boeckx M, Ceulemans E, Lauwerys RR. Urinary excretion of mercury after occupational exposure to mercury vapor and influence of the chelating agent meso-2,3-dimercaptosuccininc acid (DMSA). Br J Ind Med 1992; 247–253
- Aposhian HV, Aposhian MM. Meso-2,3-dimercaptosuccinic acid: chemical, pharmacological, and toxicological properties of an orally effective metal chelating agent. Annu Rev Pharamacol Toxicol 1990; 30: 279–306
- Aposhian HV, Maiorino RM, Gonzalez-Ramirez D, Zuniga-Charles M, Xu Z, Hurlbut KM, Junco-Munoz P, Dart RC, Aposhian MM. Mobilization of heavy metals by newer therapeutically useful chelating agents. Toxicology 1995; 97: 23–38
- Magos L. The effects of dimercaptosuccinic acid on the excretion and distribution of mercury in rats and mice treated with mercuric chloride and methylmercury chloride. Br J Pharmacol 1976; 56: 479–84
- Garza-Ocanas L, Torres-Alanis O, Pineyro-Lopez A. Urinary mercury in 12 cases of cutaneous mercurious chloride (calomel) exposure: effect of DMPS therapy. Clin Toxicol 1997; 35(6)635–655
- Bluhm RE, Bobbitt RG, Welch LW, Wood AJ, Bonfiglio JF, Sarzen C, Heath AJ, Branch RA. Elemental mercury vapor toxicity, treatment, and prognosis after acute, intensive exposure in chloralkali plant workers. Part 1: history, neuropsychological findings and chelator effects. Hum Exp Toxicol 1992; 11: 201–210
- Forman J, Moline J, Cernichiari E, Sayegh S, Torres JC, Landrigan MM, Hudson J, Adel HN, Landrigan PJ. A cluster of pediatric metallic mercury exposure cases treated with meso-2,3-dimercaptosuccinic acid (DMSA). Environ Health Perspect 2000; 108: 575–7